Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
R1 RCM
(NASDAQ:RCM)
Intraday
$11.82
0
[0.00%]
15 minutes delayed
Get Report
Watch
Perks
Buy
Compare Brokers
$11.82
0
[0.00%]
Last update: 4:00PM
Get Real Time Here
Get Report
Watch
Q1 2024 Earnings in 12 days from now on Wed May 8th, before the market open
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for R1 RCM Stock (NASDAQ:RCM)
R1 RCM Stock (NASDAQ: RCM)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, April 10, 2024
Cantor Fitzgerald Reiterates Overweight on R1 RCM, Maintains $20 Price Target
Benzinga Newsdesk
-
Apr 10, 2024, 10:25AM
Keybanc Downgrades R1 RCM to Sector Weight
Benzinga Newsdesk
-
Apr 10, 2024, 4:46AM
Friday, April 05, 2024
The Latest Analyst Ratings For R1 RCM
Benzinga Insights
-
Apr 5, 2024, 1:00PM
Guggenheim Maintains Buy on R1 RCM, Lowers Price Target to $15
Benzinga Newsdesk
-
Apr 5, 2024, 10:34AM
Monday, April 01, 2024
Truist Securities Maintains Hold on R1 RCM, Maintains $16 Price Target
Benzinga Newsdesk
-
Apr 1, 2024, 8:56AM
Tuesday, March 26, 2024
Morgan Stanley Reiterates Overweight on R1 RCM, Maintains $17 Price Target
Benzinga Newsdesk
-
Mar 26, 2024, 12:16PM
Wednesday, March 20, 2024
R1 RCM shares are trading higher after Citigroup upgraded the stock from Neutral to Buy and announced a $16 price target.
Benzinga Newsdesk
-
Mar 20, 2024, 9:24AM
Analyst Scoreboard: 12 Ratings For R1 RCM
Benzinga Insights
-
Mar 20, 2024, 8:00AM
Canaccord Genuity Maintains Buy on R1 RCM, Lowers Price Target to $16
Benzinga Newsdesk
-
Mar 20, 2024, 7:45AM
Citigroup Upgrades R1 RCM to Buy, Announces $16 Price Target
Benzinga Newsdesk
-
Mar 20, 2024, 5:33AM
Monday, March 11, 2024
R1 RCM Forms Special Committee To Evaluate Strategic Alternatives
Benzinga Newsdesk
-
Mar 11, 2024, 8:11AM
Alphabet, Dover And 2 Other Stocks Insiders Are Selling
Avi Kapoor
-
Mar 11, 2024, 8:10AM
Thursday, March 07, 2024
RBC Capital Reiterates Outperform on R1 RCM, Maintains $19 Price Target
Benzinga Newsdesk
-
Mar 7, 2024, 9:44AM
Tuesday, March 05, 2024
Cantor Fitzgerald Reiterates Overweight on R1 RCM, Maintains $20 Price Target
Benzinga Newsdesk
-
Mar 5, 2024, 12:39PM
Truist Securities Downgrades R1 RCM to Hold, Announces $16 Price Target
Benzinga Newsdesk
-
Mar 5, 2024, 5:56AM
Friday, March 01, 2024
Citigroup Maintains Buy on R1 RCM, Raises Price Target to $16
Benzinga Newsdesk
-
Mar 1, 2024, 12:21PM
Thursday, February 29, 2024
Keybanc Maintains Overweight on R1 RCM, Raises Price Target to $17
Benzinga Newsdesk
-
Feb 29, 2024, 11:34AM
Wednesday, February 28, 2024
Assessing R1 RCM: Insights From 10 Financial Analysts
Benzinga Insights
-
Feb 28, 2024, 7:00AM
Barclays Downgrades R1 RCM to Equal-Weight, Maintains Price Target to $14
Benzinga Newsdesk
-
Feb 28, 2024, 6:09AM
Evercore ISI Group Downgrades R1 RCM to In-Line, Raises Price Target to $16
Benzinga Newsdesk
-
Feb 28, 2024, 6:00AM
Tuesday, February 27, 2024
Healthcare IT-R1 RCM's Shareholder Says $13.75/Share Deal Offer Significantly Undervalues The Company
Vandana Singh
-
Feb 27, 2024, 1:06PM
R1 RCM Expects FY24 Revenue of $2.625B-$2.675B Vs $2.69B Est
Benzinga Newsdesk
-
Feb 27, 2024, 7:12AM
R1 RCM Q4 Sales $575.10M Miss $578.69M Estimate
Benzinga Newsdesk
-
Feb 27, 2024, 7:10AM
Earnings Scheduled For February 27, 2024
Benzinga Insights
-
Feb 27, 2024, 5:01AM
Monday, February 26, 2024
Coliseum Capital Issues Open Letter To Board Of R1 RCM On Offer By New Mountain To Acquire The Company For $13.75 Per Share; Believes Offer Significantly Undervalues R1 RCM
Benzinga Newsdesk
-
Feb 26, 2024, 3:57PM
US Stocks Pause, Alphabet Falls On Gemini Woes, Tesla, Bitcoin Rally: What's Driving Markets Monday?
Piero Cingari
-
Feb 26, 2024, 2:35PM
Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Avi Kapoor
-
Feb 26, 2024, 1:57PM
Leerink Partners Initiates Coverage On R1 RCM with Outperform Rating, Announces Price Target of $14
Benzinga Newsdesk
-
Feb 26, 2024, 8:32AM
R1 RCM shares are trading higher after the company received an acquisition offer for the company valued at $13.75 per share.
Luke J Jacobi
-
Feb 26, 2024, 8:27AM
New Mountain Investments V SaidJan 26 Waiver Request Included Proposal Which Included Proposed Purchase Price Of $13.75 Per Share In Cash For R1 RCM
Charles Gross
-
Feb 26, 2024, 7:32AM
Thursday, February 01, 2024
Jefferies Says LBO Analysis Of R1 RCM Suggests An Acquisition Could Generate 20%+ IRR Over 5-Year Period, Analysis Assumes 40% Takeout Premium
Benzinga Newsdesk
-
Feb 1, 2024, 1:09PM
Monday, January 08, 2024
R1 RCM expects Q4 Revenue of approximately $563M-$567M Versus Consensus Of $585.82M And GAAP Operating income of $36M-$39M, GAAP net loss of $(8)M-$(10)M and adjusted EBITDA of $163M-$166M
Benzinga Newsdesk
-
Jan 8, 2024, 7:39AM
Friday, January 05, 2024
Keybanc Maintains Overweight on R1 RCM, Lowers Price Target to $13
Benzinga Newsdesk
-
Jan 5, 2024, 5:20AM
Wednesday, January 03, 2024
What 10 Analyst Ratings Have To Say About R1 RCM
Benzinga Insights
-
Jan 3, 2024, 1:01PM
Barclays Initiates Coverage On R1 RCM with Overweight Rating, Announces Price Target of $14
Benzinga Newsdesk
-
Jan 3, 2024, 5:36AM
Friday, December 15, 2023
Morgan Stanley Upgrades R1 RCM to Overweight, Lowers Price Target to $17
Benzinga Newsdesk
-
Dec 15, 2023, 5:34AM
Wednesday, December 13, 2023
JP Morgan Downgrades R1 RCM to Neutral, Lowers Price Target to $11
Benzinga Newsdesk
-
Dec 13, 2023, 7:07AM
Thursday, December 07, 2023
Wall Street Revels In Gains As AI, Tech Titans Surge; Dollar Plunges Against Yen: What's Driving Markets Thursday?
Piero Cingari
-
Dec 7, 2023, 2:05PM
RBC Capital Reiterates Outperform on R1 RCM, Maintains $19 Price Target
Benzinga Newsdesk
-
Dec 7, 2023, 12:21PM
Canaccord Genuity Reiterates Buy on R1 RCM, Maintains $17 Price Target
Benzinga Newsdesk
-
Dec 7, 2023, 10:41AM
Wednesday, December 06, 2023
R1 RCM Has Agreed To Acquire Acclara For $675M In Cash And Warrants To Purchase 12.2M Shares Of R1 Stock
Benzinga Newsdesk
-
Dec 6, 2023, 6:02AM
Monday, December 04, 2023
What 6 Analyst Ratings Have To Say About R1 RCM
Benzinga Insights
-
Dec 4, 2023, 2:00PM
Cantor Fitzgerald Reiterates Overweight on R1 RCM, Maintains $20 Price Target
Benzinga Newsdesk
-
Dec 4, 2023, 9:15AM
R1 Completes Restatement Of Previously Issued Financial Statements; No Impact On R1's Cash, Business Operations Or 2023 Outlook
Benzinga Newsdesk
-
Dec 4, 2023, 8:18AM
Friday, November 17, 2023
R1 RCM Receives Notice Of Filing Delinquency from Nasdaq
Benzinga Newsdesk
-
Nov 17, 2023, 4:01PM
Friday, November 03, 2023
Shares of healthcare equipment and healthcare provider stocks are trading higher amid overall market strength. Strength may also be attributed to Cardinal Health after the company reported better-than-expected Q1 financial results.
Benzinga Newsdesk
-
Nov 3, 2023, 3:33PM
RBC Capital Maintains Outperform on R1 RCM, Lowers Price Target to $19
Benzinga Newsdesk
-
Nov 3, 2023, 3:18PM
Morgan Stanley Maintains Equal-Weight on R1 RCM, Lowers Price Target to $17.5
Benzinga Newsdesk
-
Nov 3, 2023, 9:20AM
Keybanc Maintains Overweight on R1 RCM, Lowers Price Target to $18
Benzinga Newsdesk
-
Nov 3, 2023, 7:28AM
Thursday, November 02, 2023
R1 RCM Says Track To Achieve Guidance For 2023, With Revenue Of $2.255B-$2.275B
Benzinga Newsdesk
-
Nov 2, 2023, 7:27AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch